Argininosuccinate lyase is a potential therapeutic target in breast cancer

Hau Lun Huang, Wei Ching Chen, Hui Ping Hsu, Chien Yu Cho, Yu Hsuan Hung, Chih Yang Wang, Ming Derg Lai

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Arginine is a non-essential amino acid that modulates nitric oxide production and cancer homeostasis. In our previous study, we observed that blocking argininosuccinate lyase (ASL) attenuates tumor progression in liver cancer. However, the role of ASL in human breast cancer has been studied to a lesser degree. In the present study, we investigated the effect of targeting ASL in breast cancer. We found that ASL was induced by ER stress and was significantly upregulated in breast cancer tissues compared to that in the corresponding normal tissues. Downregulation of ASL inhibited the growth of breast cancer in vitro and in vivo. The level of cell cyclerelated gene, cyclin A2, was reduced and was accompanied by a delay in G2/M transition. ASL shRNA-induced cell inhibition was rescued by exogenous cyclin A2. Furthermore, autophagy was observed in the cells expressing ASL shRNA, and inhibition of autophagy reduced cell growth, indicating that autophagy played a cell survival role in the ASL knockdown cells. Moreover, inhibition of ASL reduced NO content. Introduction of the NO donor partially restored the growth inhibition by ASL shRNA. Thus, the mechanism induced by ASL shRNA which occurred in human breast cancer may be attributed to a decrease in cyclin A2 and NO.

Original languageEnglish
Pages (from-to)3131-3139
Number of pages9
JournalOncology Reports
Volume34
Issue number6
DOIs
Publication statusPublished - Dec 1 2015
Externally publishedYes

Fingerprint

Neoplastic Gene Expression Regulation
Cyclin A2
Argininosuccinate Lyase
Cyclin A
Endoplasmic Reticulum Stress
Autophagy
Tumor Cell Line
Endoplasmic Reticulum
Small Interfering RNA
Arginine
Nitric Oxide
Cell Proliferation
Breast Neoplasms
Therapeutics
Growth

Keywords

  • Argininosuccinate lyase
  • Autophagy
  • Breast cancer
  • Cyclin A
  • Endoplasmic reticulum
  • Nitric oxide

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Huang, H. L., Chen, W. C., Hsu, H. P., Cho, C. Y., Hung, Y. H., Wang, C. Y., & Lai, M. D. (2015). Argininosuccinate lyase is a potential therapeutic target in breast cancer. Oncology Reports, 34(6), 3131-3139. https://doi.org/10.3892/or.2015.4280

Argininosuccinate lyase is a potential therapeutic target in breast cancer. / Huang, Hau Lun; Chen, Wei Ching; Hsu, Hui Ping; Cho, Chien Yu; Hung, Yu Hsuan; Wang, Chih Yang; Lai, Ming Derg.

In: Oncology Reports, Vol. 34, No. 6, 01.12.2015, p. 3131-3139.

Research output: Contribution to journalArticle

Huang, HL, Chen, WC, Hsu, HP, Cho, CY, Hung, YH, Wang, CY & Lai, MD 2015, 'Argininosuccinate lyase is a potential therapeutic target in breast cancer', Oncology Reports, vol. 34, no. 6, pp. 3131-3139. https://doi.org/10.3892/or.2015.4280
Huang, Hau Lun ; Chen, Wei Ching ; Hsu, Hui Ping ; Cho, Chien Yu ; Hung, Yu Hsuan ; Wang, Chih Yang ; Lai, Ming Derg. / Argininosuccinate lyase is a potential therapeutic target in breast cancer. In: Oncology Reports. 2015 ; Vol. 34, No. 6. pp. 3131-3139.
@article{c5c31d7c084c40dbbfecc018d962ae48,
title = "Argininosuccinate lyase is a potential therapeutic target in breast cancer",
abstract = "Arginine is a non-essential amino acid that modulates nitric oxide production and cancer homeostasis. In our previous study, we observed that blocking argininosuccinate lyase (ASL) attenuates tumor progression in liver cancer. However, the role of ASL in human breast cancer has been studied to a lesser degree. In the present study, we investigated the effect of targeting ASL in breast cancer. We found that ASL was induced by ER stress and was significantly upregulated in breast cancer tissues compared to that in the corresponding normal tissues. Downregulation of ASL inhibited the growth of breast cancer in vitro and in vivo. The level of cell cyclerelated gene, cyclin A2, was reduced and was accompanied by a delay in G2/M transition. ASL shRNA-induced cell inhibition was rescued by exogenous cyclin A2. Furthermore, autophagy was observed in the cells expressing ASL shRNA, and inhibition of autophagy reduced cell growth, indicating that autophagy played a cell survival role in the ASL knockdown cells. Moreover, inhibition of ASL reduced NO content. Introduction of the NO donor partially restored the growth inhibition by ASL shRNA. Thus, the mechanism induced by ASL shRNA which occurred in human breast cancer may be attributed to a decrease in cyclin A2 and NO.",
keywords = "Argininosuccinate lyase, Autophagy, Breast cancer, Cyclin A, Endoplasmic reticulum, Nitric oxide",
author = "Huang, {Hau Lun} and Chen, {Wei Ching} and Hsu, {Hui Ping} and Cho, {Chien Yu} and Hung, {Yu Hsuan} and Wang, {Chih Yang} and Lai, {Ming Derg}",
year = "2015",
month = "12",
day = "1",
doi = "10.3892/or.2015.4280",
language = "English",
volume = "34",
pages = "3131--3139",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "6",

}

TY - JOUR

T1 - Argininosuccinate lyase is a potential therapeutic target in breast cancer

AU - Huang, Hau Lun

AU - Chen, Wei Ching

AU - Hsu, Hui Ping

AU - Cho, Chien Yu

AU - Hung, Yu Hsuan

AU - Wang, Chih Yang

AU - Lai, Ming Derg

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Arginine is a non-essential amino acid that modulates nitric oxide production and cancer homeostasis. In our previous study, we observed that blocking argininosuccinate lyase (ASL) attenuates tumor progression in liver cancer. However, the role of ASL in human breast cancer has been studied to a lesser degree. In the present study, we investigated the effect of targeting ASL in breast cancer. We found that ASL was induced by ER stress and was significantly upregulated in breast cancer tissues compared to that in the corresponding normal tissues. Downregulation of ASL inhibited the growth of breast cancer in vitro and in vivo. The level of cell cyclerelated gene, cyclin A2, was reduced and was accompanied by a delay in G2/M transition. ASL shRNA-induced cell inhibition was rescued by exogenous cyclin A2. Furthermore, autophagy was observed in the cells expressing ASL shRNA, and inhibition of autophagy reduced cell growth, indicating that autophagy played a cell survival role in the ASL knockdown cells. Moreover, inhibition of ASL reduced NO content. Introduction of the NO donor partially restored the growth inhibition by ASL shRNA. Thus, the mechanism induced by ASL shRNA which occurred in human breast cancer may be attributed to a decrease in cyclin A2 and NO.

AB - Arginine is a non-essential amino acid that modulates nitric oxide production and cancer homeostasis. In our previous study, we observed that blocking argininosuccinate lyase (ASL) attenuates tumor progression in liver cancer. However, the role of ASL in human breast cancer has been studied to a lesser degree. In the present study, we investigated the effect of targeting ASL in breast cancer. We found that ASL was induced by ER stress and was significantly upregulated in breast cancer tissues compared to that in the corresponding normal tissues. Downregulation of ASL inhibited the growth of breast cancer in vitro and in vivo. The level of cell cyclerelated gene, cyclin A2, was reduced and was accompanied by a delay in G2/M transition. ASL shRNA-induced cell inhibition was rescued by exogenous cyclin A2. Furthermore, autophagy was observed in the cells expressing ASL shRNA, and inhibition of autophagy reduced cell growth, indicating that autophagy played a cell survival role in the ASL knockdown cells. Moreover, inhibition of ASL reduced NO content. Introduction of the NO donor partially restored the growth inhibition by ASL shRNA. Thus, the mechanism induced by ASL shRNA which occurred in human breast cancer may be attributed to a decrease in cyclin A2 and NO.

KW - Argininosuccinate lyase

KW - Autophagy

KW - Breast cancer

KW - Cyclin A

KW - Endoplasmic reticulum

KW - Nitric oxide

UR - http://www.scopus.com/inward/record.url?scp=84943753397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943753397&partnerID=8YFLogxK

U2 - 10.3892/or.2015.4280

DO - 10.3892/or.2015.4280

M3 - Article

C2 - 26397737

AN - SCOPUS:84943753397

VL - 34

SP - 3131

EP - 3139

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 6

ER -